BioTuesdays

Echelon reiterates Acasti Pharma, Antibe Therapeutics as top picks

Echelon Wealth Partners reiterated top pick status to Acasti Pharma (TSXV:ACST) and Antibe Therapeutics (TSXV:ATE).

Acasti is developing an omega-3-based therapeutic for the treatment of hyperglyceridemia. Analyst Doug Loe maintained his “speculative buy” rating and $4.00 price target for Acasti, whose stock closed at $2.86 on Jan. 8.

He also maintained his “speculative buy” rating and $1.40 price target for Antibe, which is developing a pipeline of non-addictive pain and inflammation therapeutics. The stock closed at 47 cents on Jan. 8.

Sign up for the BioTuesdays weekly newsletter

Get the latest news on the healthcare industry’s corporate and clinical developments, executive moves, and market updates. Every Tuesday, in your inbox.